Inclusive of all taxes
Ceftriaxone Sodium & Tazobactam Sodium for Injection 281.5mg is a potent antimicrobial agent combining a third-generation cephalosporin antibiotic (Ceftriaxone Sodium) with a beta-lactamase inhibitor (Tazobactam Sodium). This injectable formulation is presented as a dry powder intended for intravenous or intramuscular administration after reconstitution. The synergistic action broadens the antibacterial spectrum, effectively targeting multi-resistant bacteria that secrete beta-lactamase enzymes, which typically degrade conventional cephalosporins. Ideal for treatment of complicated infections such as severe respiratory, urinary tract, skin and soft tissue, intra-abdominal infections, and septicemia in clinical settings, this combination delivers 281.5 mg per vial - approximately 250 mg of Ceftriaxone Sodium and 31.5 mg of Tazobactam Sodium. Its beta-lactamase inhibitory action significantly enhances ceftriaxone's stability, ensuring better bacterial eradication against resistant strains common in hospital-acquired infections. The product is designed for healthcare professionals requiring reliable broad-spectrum antibiotic therapy with improved efficacy against resistant pathogens, making it essential for hospitals, clinics, and diagnostic centers dealing with serious bacterial infections.
Key Features
| Features | Description |
|---|---|
| Form | Dry powder for injection |
| Total Strength | 281.5 mg per vial (combined Ceftriaxone Sodium and Tazobactam Sodium) |
| Ceftriaxone Sodium Content | Approximately 250 mg per vial |
| Tazobactam Sodium Content | Approximately 31.5 mg per vial |
| Administration Route | Intravenous or Intramuscular after reconstitution |
| Antibiotic Generation | Third-generation cephalosporin combined with beta-lactamase inhibitor |
| Antibacterial Spectrum | Broad spectrum, effective against beta-lactamase producing bacteria |
| Therapeutic Applications | Treatment of serious infections including respiratory tract, urinary tract, intra-abdominal, skin and soft tissue infections, and septicemia |
| Packaging | Sterile single-use vial containing dry powder |
| Attributes | Description |
|---|---|
| Chemical Components | Ceftriaxone Sodium and Tazobactam Sodium |
| Dosage Strength | 281.5 mg combined per vial |
| Physical State | Lyophilized powder for injection |
| Color | White to off-white powder |
| Solubility | Reconstituted with sterile water or suitable diluents for injection |
| Storage Conditions | Store below 30°C, protect from moisture |
| Shelf Life | Typically 2 years from manufacture date when stored properly |
| Packaging Details | Single-dose vial with sterile packaging |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The injection contains approximately 250 mg of Ceftriaxone Sodium and 31.5 mg of Tazobactam Sodium, making a combined dosage strength of 281.5 mg per vial.
It is primarily used to treat complicated bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, and septicemia caused by susceptible and beta-lactamase producing bacteria.
The dry powder must be reconstituted with a suitable sterile diluent and administered via intravenous or intramuscular injection by healthcare professionals.
Tazobactam Sodium acts as a beta-lactamase inhibitor, protecting Ceftriaxone from enzymatic degradation by beta-lactamase producing bacteria, thereby enhancing efficacy against resistant bacterial strains.
The product should be stored in a cool and dry place below 30°C, shielded from moisture to maintain potency and sterility.
Country Of Origin: India
Ceftriaxone Sodium & Tazobactam Sodium for Injection 281.5 mg is a combination antibiotic formulation that pairs a third-generation cephalosporin with a beta-lactamase inhibitor. This combination enhances the antibiotic's effectiveness against a broad spectrum of bacteria, including those that produce beta-lactamase enzymes.
Key Features:
Form: Dry powder for injection.
Strength: 281.5 mg (combined dosage of Ceftriaxone Sodium and Tazobactam Sodium).
Ceftriaxone Sodium: Typically around 250 mg.
Tazobactam Sodium: Typically around 31.5 mg.
Inclusive of all taxes
You Save: 0
